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After the detection of microglia by Pio del Rio Hortega in 1919 (del Rio-Hortega,
1919; Sierra et al., 2016), several decades passed until researchers took an interest
in the brain‘s resident macrophages. While being known for active immune defense
and phagocytosis (Kettenmann et al., 2011), the importance of microglia for plasticity,
learning and also for specific diseases in humans only became apparent in recent
years (Salter, Stevens, 2017).
1.1 Formation and morphology
Mikroglia develop from the myeloid progenitor cells of the yolk sac (Ginhoux et al.,
2010). By systematically eliminating synapses and therefore increasing synap-
tic turnover, they influence the regular development of the brain (Paolicelli et al.,
2011; Wu et al., 2015) and subsequently memory-associated functions like learning
and synaptic plasticity (Wake et al., 2009; Schafer et al., 2012; Zhan et al., 2014).
Furthermore, microglia regulate neurogenesis in the adult brain (Sierra et al., 2010).
Despite their vital functions, the phagocytes of the brain are long lived (Spittau,
2017). Revelations in 14C analyses of microglia potentially being decades old led
to the assumption that microglia are the slowest dividing immune cells known to
date (Réu et al., 2017). However, repopulation was shown repeatedly after CSF1R
antagonist-mediated depletion (O’Neil et al., 2018).
Interestingly, transcriptomic studies exhibited that the global gene expression
profile of adult microglia in the healthy brain was regionally heterogeneous, implying
region-specific functions (Grabert et al., 2016). Additionally, the impact of age and
diet on microglial function and morphology is dependent on the affected brain area
(Spencer et al., 2019).
Currently, three states of microglia are being differentiated:
The so-called resting microglia can be found ubiquitously in the brain. In con-
trast to their designation, these cells are highly dynamic (Nimmerjahn et al., 2005).
Characterized by a ramified morphology, they constantly scan their surroundings with
their long processes, inspecting the integrity of synaptic connections (Graeber, 2010).
Creating a network that spans the whole CNS (Lawson et al., 1990), microglia are
able to survey the whole brain parenchyma over a course of a few hours (Nimmerjahn
et al., 2005). Resting microglia can always transform into the activated form. The
change is triggered by different factors like proinflammatory cytokines, cell necrosis-
inducing constituents, lipopolysaccharides, and changes in extracellular potassium
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Figure 1.1: Morphological states of microglia. A.: Ramified microglia. B: Activated
microglia. C: Senescent microglia. Scale bars: 25µm.
concentrations (Verkhratsky, Butt, 2013).
The activated form is defined by shortened ramification, an increased size of cell
somata, antigen presentation to MHCII-proteins and expression of proinflammatory
cytokines (Lue, 2001; Cho et al., 2011). Since there are activated microglia at
amyloid plaques in brains of Alzheimer disease patients, many regard the disease as
neuroinflammatory (Heneka et al., 2015; Kinney et al., 2018). However, randomized
prospective studies were not able to find declining symptoms when treated with
non-steroidal anti-inflammatory drugs (NSAIDs, Martin et al. (2008); Wang et al.
(2015)). Also, new data from our group show that microglial activation in Alzheimer
disease brains occurs late in the disease and is restricted to amyloid plaques (Streit
et al., 2018).
1.2 Microglia and aging
A third state of microglia is found in the aging brain and is thought to reflect microglial
senescence. This state is characterized by dystrophy of microglia, which is defined
by swelling of processes and loss of ramification (Streit et al., 2004). Initially, cells
were thought to be fragmented. However, it was shown that processes are thinning
below the resolution of light microscopy (Tischer et al., 2016), reflecting damage of
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the cytoskeleton.
The factors that may lead to or accelerate microglial aging are not currently
known. Yet, while aging, microglia seem to lose their neuroprotective functions, which
they convey for example through the secretion of neuroprotective factors (Parkhurst
et al., 2013). Furthermore, in Alzheimer’s disease, an enhanced neurofibrillary
degeneration was shown in the presence of dystrophic microglia (Streit et al., 2009).
A forced turnover induced by CSF1R-induced depletion of microglial cells reduced
lipofuscin accumulation and also led to normalization of age-associated increased
CD68-expression (O’Neil et al., 2018). However, microglia did not exhibit an aging
phenotype when being affected by telomer dysfunction, which resembles a state of
advanced aging (Khan et al., 2015).
Changes appear not only at a morphological level but also affect microglial gene
expression. Microglia-specific genes, in contrast to neuronal genes, are considered
to be good predictors for the biological age of the human brain (Soreq et al., 2017).
Furthermore, the age-associated mRNA signature was shown to be robust, only
partially being affected in newly emerging cells after CSF1R-induced depletion (O’Neil
et al., 2018). Studies examining region-specific alterations in microglia demonstrated
that especially hippocampal microglia exhibited greater sensitivity to age-related
changes (Grabert et al., 2016).
While microglial aging is evolving as a novel field, experiments still fail to fully
mimic this process in mice (Franco Bocanegra et al., 2018; Navarro et al., 2018),
therefore rendering studies in human tissue inevitable.
A deficiency of TREM2, a molecule which was shown to increase phagocytosis
and secretion of anti-inflammatory cytokines (Neumann, Takahashi, 2007), leads to
impaired microglial function and increases the accumulation of beta-amyloid (Wang
et al., 2015). Furthermore TREM2-KO-mice showed lower transcription levels of
the microglial markers IBA1 (AIF1) and TMEM119 and exhibited a decrease in
IBA1-positive microglia (Linnartz-Gerlach et al., 2018). With some alleles of TREM2
being a risk factor for Alzheimer’s disease (Guerreiro et al., 2012; Jonsson et al.,
2013), TREM2 serves as a binding partner for Apolipoprotein E (Atagi et al., 2015),
whose ε4 subtype is among the strongest risk factors for Alzheimer’s disease (Roses,
1996). Findings that the regulation of microglial immune defence operates through
apolipoprotein E via the LDL-receptor (Pocivavsek et al., 2009) emphasize the
association of lipid metabolism and the development of Alzheimer’s disease.
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1.3 Microglia and obesity
The influence of nutrition on microglial function has been discussed, not only in
relation to microglial senescence.
Already the maturation of microglia is dependent on short-chained fatty acids,
which are produced by the microbiome in the intestines (Erny et al., 2015). Peroxi-
somes, which are necessary for the oxidative degradation of fatty acids, were shown
to be vulnerable for age-dependent changes since loss of peroxisomes and the
concentration of long-chain fatty acids correlate with the severeness of the Alzheimer
disease (Kou et al., 2011; Scott et al., 2016). Most studies examining microglia in
obesity have focused on the rodent hypothalamus demonstrating microglial activation
already after short term application (2–3 weeks) of a high-fat diet (Thaler et al., 2012;
Valdearcos et al., 2017).
In contrast, microglial activation in the hippocampus was only exhibited after
long-term application (>20 weeks) just like accompanying cognitive deficits (Lu et al.,
2011; Jeon et al., 2012; Luca de et al., 2016; Cai et al., 2016). As a morphological
correlate, an increased appearance of IBA1 in rodent hippocampi was detected, after
imitating the effects of a long term (eight months) western diet in mice (Graham et al.,
2016). Interestingly no substantial change in microglial number was found (Cope
et al., 2018).
Diminishing cognitive function has been reported in overweight individuals (Siervo
et al., 2011; Bischof, Park, 2015), even in the absence of diabetes and metabolic
syndrome (Cope et al., 2018). As a functional correlate, high-fat diet was shown
to lead to a reduction in markers of synaptic plasticity and neuronal growth such
as BDNF (Lindqvist et al., 2006). Furthermore, several studies have demonstrated
increased internalization of synapses by microglia after consumption of a high-fat
diet (Bocarsly et al., 2015; Hao et al., 2016).
In relation to obesity, astrocytes were not activated by saturated fatty acids (ad-
ministered by enteric gavage) whereas microglia were (Valdearcos et al., 2014).
Further studies also found no astrocytic activation, while either stable (Cope et al.,
2018) or a decreased neurogenesis (Lindqvist et al., 2006; Murata et al., 2017) was
calculated. Furthermore, it was demonstrated that a partial knockdown of CX3CR1,
the microglial fractalkine receptor which promotes reciprocal neuron–microglial sig-
nalling (Paolicelli et al., 2014), prevented obesity associated cognitive decline and
microglial activation. This suggests an active role of microglia in cognitive impairment
(Cope et al., 2018).
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However, most studies focus on rodent models. The investigation of obesity-
induced alterations on microglia in human brains is quite rare. Baufeld and colleagues
were able to find a dystrophy-like phenotype, which they compared to the one found
in chronic systemic diseases (Baufeld et al., 2016). A potential structural correlate for
the cognitive restrictions in obese human individuals was found in the significantly
decreased size of hippocampi (Jagust et al., 2005; Raji et al., 2010).
Since obesity has been shown to increase the risk of dementia independent of
Type 2-Diabetes (Whitmer et al., 2008) and to partially accelerate aging (Zhang et al.,
2015), we were interested to investigate if an accelerated microglial senescence
occured in obese individuals. Being not only heavily affected, but also one of the
first parts of the brain to suffer damage in Alzheimer’s disease and other forms of
dementia (Braak, Braak, 1991; Moodley, Chan, 2014), we chose to examine the
hippocampus.
1.4 Hippocampus
The hippocampus is located in the temporal lobe adjacent to the lateral ventricle
and part of the limbic system. Consisting of different subsections, it is essential
for the acquisition of spatial memory (Li et al., 2013). However, each hippocampal
subfield covers different functions during these memory tasks, emphasizing the pivotal
hippocampal involvement in the integration of multimodal information (Langston,
Wood, 2010).
The cornu ammonis can be separated into four different layers (CA1-CA4). The
CA1-layer is critical for the consolidation and retrieval of spatial information (Rolls,
Kesner, 2006; Vago et al., 2007), whereas the CA3-Layer (CA3) has been associated
with the process of encoding (Hunsaker et al., 2008). This region also enables rapid
associations between spatial locations or places and objects (Rolls, 2013).
The dentate gyrus is essential in the encoding of spatial information ((Lee, Kesner,
2004) as well as spatial navigation (Derrick, 2007; Kesner, 2007) and pattern separa-
tion (Leutgeb et al., 2007; Clelland et al., 2009). Neurogenesis was shown to occur in
the dentate gyrus, however it remains an ongoing discussion if it still occurs in adult
human individuals (Lee, Thuret, 2018).
The Subiculum represents the principal entity organizing the hippocampal output (Mc-
Naughton, 2006). It receives direct synaptic inputs from the hippocampal layer CA1
(Matsumoto et al., 2018). Furthermore, most efferent fibers of the hippocampus arise
in the subiculum and pass through the fornix to the mamillary body, representing the
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major output from the hippocampus. This connection also makes the hippocampus a
component of the Papez-circuit (Papez, 1995).
By studying 100µm thick sections, which are useful for the neuropathologic
evaluation of morphologic microglial changes (Streit et al., 2009), we detected varying
spatial distribution patterns of IBA1-positive microglia in human hippocampi.
1.5 IBA1
First described in 1998 (Ito et al., 1998), IBA1 has become the most commonly
employed marker for microglia. The calcium-binding protein, which is involved in
membrane ruffling and actin-cross-linking is expressed by all microglial subpopulations
(Ito et al., 1998; Sasaki et al., 2001; Walker, Lue, 2015) as well as by peripheral
macrophages (Sasaki et al., 2001; Leone et al., 2006; Köhler, 2007; Buckman et al.,
2014). Furthermore, it was demonstrated that IBA1 is not useful for identifying the
polarity of microglia since all described immune phenotypes express IBA1 (Walker,
Lue, 2015).
Despite its widespread use as a microglial marker, the exact function of IBA1 still
needs to be explored. Significantly reduced levels of IBA1 in Interferon regulatory
factor 8-(IRF8)-deficient microglia were shown while these cells exhibited increased
levels of the murine macrophage marker F4/80 (Minten et al., 2012). IRF8 is one of
the intrinsic factors that regulate the transition from a ramified microglial morphology
to an activated state (Masuda et al., 2012; Kierdorf, Prinz, 2013). Despite the
accepted hypothesis that IBA1 was involved in phagocytosis (Sasaki et al., 2001),
IRF8-deficient microglia showed no deficits in phagocytosis (Minten et al., 2012).
IBA1 is described as one of four proteins, which actually share the same genomic
sequence and apparently do not undergo post- transcriptomic changes (Deininger
et al., 2002). The best-known, AIF1, modulates proliferation of human vascular
smooth muscle cells (Chen et al., 2004).
In our sample we detected areas seemingly devoid of IBA1-staining, leading to
the hypothesis that there was a localized loss of microglia. In order to characterize
this potential loss of microglia, several markers were used to investigate microglial

















Figure 1.2: Anatomy of the human hippocampus. A: Histological overview. IBA1-stained
section with hematoxylin counterstaining. Scale bar 500µm. B: Schematic overview of
Hippocampus (Duvernoy, 2005). CA1–CA4, fields of the cornu Ammonis, DG, Dentate
Gyrus. 1. alveus; 2, stratum oriens; 3, stratum pyramidale; 3’, stratum lucidum; 4, stratum
radiatum; 5, stratum lacunosum; 6, stratum moleculare; 7, vestigial hippocampal sulcus, 8,
stratum moleculare; 9, stratum granulosum; 10, polymorphic layer; 11, fimbria; 12, margo
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Besides the established markers MHCII and CD68, especially P2ry12 and GPX1
showed reliable stability in labeling microglia in areas devoid of IBA1-staining. There-
fore, we assumed a downregulation of IBA1 rather than a localized loss of microglia
as a reason for the occurrence of IBA1-negative areas.
This thesis was designed to detect differences between microglia in lean and
obese individuals. Therefore, the second hypothesis was that these IBA1-negative
areas were overrepresented in obese individuals. However, statistically significant
alterations in the distribution of microglia e.g. increased mean empty space distances,
increased density or increased appearance of IBA1-negative areas in lean and
obese individuals in the hippocampus were not found. However, while searching
for confounding factors, we observed increased mean empty space distances and
IBA1-negative areas in individuals suffering from impairment in liver function.
1.7 Hepatic dysfunction
One of the major comorbidities in obesity is liver dysfunction.
Liver dysfunction, in general, can be caused by many upstream pathologies.
Exposure to long-term high-fat diets, high caloric intake, and increased alcohol intake
can lead to fatty liver disease and subsequently liver cirrhosis. More reasons for
liver dysfunction are (viral) hepatitis or carcinomas, either as primary liver tumors
like the hepatocellular carcinoma (HCC) and the cancer of hepatic ducts also known
as cholangiocellular carcinoma (CCC) or as hepatic metastases (e.g. colorectal
carcinomas).
Since the liver is one of the principal players in overall metabolism, impairment
in its function leads to major disruptions. Altered lipid metabolism, endocrinological
changes and insufficient synthesis of albumin and coagulation factors are among
the numerous consequences. Of particular interest is the accumulation of toxic
metabolites and therefore increased ammonia levels potentially leading to cognitive
deterioration. It is estimated, that between 60 and 80 % of patients with liver cirrhosis
suffer from a minimal manifestation of hepatic encephalopathy (Ortiz et al., 2005).
1.8 Hepatic encephalopathy
The end stage condition, where brain function is worsening, and the patients suffer
from a severe decline in cognitive function is called hepatic encephalopathy (HE). For
many years the excessive ammonia levels in the brain were considered to be the main
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factor in the disease. Ammonia is taken up by astrocytes leading to cytotoxic edema
and astrocyte dysfunction, which can be seen in the neuropathology as Alzheimer
Type II-Astrocytosis (Norenberg, 1987; Albrecht, Norenberg, 2006). The phenomena
of an astrocytic reaction in association to a condition known today as Wilson’s disease
was first described by Alois Alzheimer (1912). Subsequently, the link between an
impaired liver function and an astrocytic reaction was established (Scherer, 1932;
Adams, Foley, 1953). Alzheimer Type II-Astrocytosis is mainly found in the striatum,
the cortex and the thalamus. However, it is not found in the hippocampus (Norenberg,
1987).
While no consistent relationship between blood ammonia levels and clinical
severity of hepatic encephalopathy was found (Dam et al., 2013), functional neuro-
imaging of the brain revealed alterations in the hippocampus and related regions,
connecting the clinically characteristic deficits in attention and spatial orientation to a
neuroanatomic structure (Weissenborn et al., 2004; Arias et al., 2015).
Since the hippocampus is not affected by a reactive astrocytosis, a co-responsibility
of microglia for the arising cognitive decline in hepatic encephalopathy brain needs to
be considered.
1.9 Microglia in hepatic encephalopathy
Rodent studies mimicking hepatic encephalopathy have shown increased expression
of IBA1 (Zemtsova et al., 2011). Since microglial depletion diminished the alcohol
associated induction of pro-inflammatory genes and enhanced the induction of
anti-inflammatory genes (Walter, Crews, 2017), prolonged microglial activation was
suggested to be deleterious to surrounding cells, promoting tissue damage and cell
death. Zhao and colleagues proposed this process as being accountable for neuronal
loss in animal models of alcohol abuse (Zhao et al., 2013). Similarly, in post mortem
brains of individuals suffering from cirrhosis with and without hepatic encephalopathy,
genes modulating inflammation and microglial activation were dysregulated (Görg
et al., 2013).
In a morphological analysis, microglial cells in the white matter exhibited an
extensive, widespread fragmentation. Interestingly, in this study, only a small subset
of HE cases was characterized by microglial proliferation (Dennis et al., 2014).
Linkages between increased intake of alcohol and the development of Alzheimer’s
disease are discussed rather contradictorily. A majority of the studies evaluates a
medical history of alcohol abuse as being rather protective (Peters et al., 2008; Hersi
11
et al., 2017). However, similar brain regions and cognitive functions are affected in
Alzheimer’s disease and hepatic encephalopathy.
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2 Aims and outlines of the dissertation
This thesis was initiated to search for differences in microglia of obese and lean
individuals. During the initial analyses of IBA1-stained thick sections of hippocampi,
local areas fully devoid of IBA1-expression were detected. On the basis of this novel
observation, the following hypotheses were formulated:
1. IBA1-negative areas represent a localized loss of microglia.
2. IBA1-negative areas occur more often in obese individuals.
Microglial markers showed remaining immunoreactivity for P2ry12 and GPX1, demon-
strating continued presence of microglia. Furthermore, we were not able to detect
an increase or decrease in density or changes in the mean empty space distance in
obese compared to lean individuals. However, hepatic dysfunction was detected as
a major factor to influence microglial distribution. Impairment in hepatic function is
a common comorbidity in obesity. While cognitive deficits have been described to
occur more frequently in obese individuals (Siervo et al., 2011; Bischof, Park, 2015),
morphological analyses in brains of individuals suffering from hepatic encephalopathy
detected an extensive, widespread fragmentation of the microglial cells in the white
matter (Dennis et al., 2014). Thus, a third hypothesis arose, i.e. that an accelerated
microglial aging was part of the pathophysiological process:
3. The mean empty space distance increases with age.
The changes found in the mean empty space distance between microglial cells
were independent of aging, therefore a connection between accelerated microglial
senescence and cognitive decline in hepatic encephalopathy cannot be presumed.
As pointed out above, microglia are currently differentiated in the three phenotypes
ramified, activated and senescent. However, it is an ongoing discussion if these
three states can describe the full portfolio of microglial morphology and function or
rather if there are disease-specific phenotypes. The constant renewal of microglia
can cause not only the individual cells to change but also their spatial layout to rapidly
adapt to altering situations (Askew et al., 2017). Therefore, a more extensive view on
microglial morphology and distribution is needed.
The characterization of local loss of IBA1-expression is a new morphological
feature in microglia and therefore questions the single use of IBA1 as a gold standard
in detecting microglia. Emphasizing the importance of studying microglia in human
individuals, we demonstrated a microglial reaction concerning their overall distribution
to a chronic systemic disease such as liver dysfunction.
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In future studies, microglial changes following chronic systemic diseases in
humans need to be studied and further understood, not only to distinguish the
different confounding factors but also to be able to reliably identify changes in
neurodegenerative diseases, which are solely based on the condition.
14
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H I G H L I G H T S
• Areas, that were negative for IBA1, contained P2YR12 and GPX1-positive microglia.• Loss of IBA1-immunophenotype does not occur as a consequence of microglial senescence.• Number and extent of IBA1-negative regions was increased in obese cases.• Hepatic dysfunction strongly impacts the distribution of microglial cells.





A B S T R A C T
Microglia, the brain’s resident immune cells, exhibit constitutive expression of the ionized calcium binding
adaptor molecule 1 (IBA1), a cytoplasmic protein with actin and calcium-binding functions involved in mem-
brane ruffling. Microglia are long-lived cells that exhibit a senescent morphology (dystrophy) with aging, which
may be indicative of cell dysfunction. It has been reported that dystrophy of IBA1-positive microglia is ex-
acerbated in obese humans. Our own preliminary studies of microglia in the medial temporal lobe of obese
subjects have revealed another microglial abnormality, which is the loss of IBA1 immunoreactivity that can
create large areas in the brain seemingly devoid of all microglial cells. Here, we systematically compared mi-
croglial appearance in human hippocampi derived from obese individuals compared to controls (nobese= 33,
nnon-obese= 30). In both groups, we found areas that were negative for IBA1, but contained P2YR12 and glu-
tathione-peroxidase 1 (GPX)-positive microglia. The number and extent of IBA1-negative regions was increased
in obese cases. Since some cases of non-obese individuals also exhibited loss of IBA-1 immunoreactivity, we
searched for possible confounders and found that hepatic dysfunction strongly impacts the distribution of mi-
croglial cells: By computational analysis of scanned IBA1-stained sections, we detected increased Mean Empty
Space distances (p=0.016) and IBA1-negative areas (p=0.090) which were independent from the cause of
liver dysfunction, but also from aging. Thus, we report on a novel type of microglia pathological change, i.e.
localized loss of IBA1 that is linked, at least in part, to obesity and hepatic dysfunction.
1. Introduction
Microglia are the brain’s resident macrophages and are crucial for
plasticity and learning (Sierra et al., 2010, Parkhurst et al., 2013, Zhan
et al., 2014). Deriving from yolk sac progenitors (Ginhoux et al., 2010,
Kierdorf et al., 2013), microglia show limited self-renewal and thereby
serve as long-living immune cells in the brain, while exhibiting age-
dependent morphological changes (Spittau 2017). We have previously
demonstrated the widespread appearance of microglial dystrophy (se-
nescent morphology) in the brains of AD patients (Streit et al., 2009).
Studies have demonstrated that obesity expedites various processes of
aging (Zhang et al., 2015, Jura and Kozak, 2016) and an increasing
appearance of atherosclerotic alterations promotes the development of
vascular dementia (Gorelick et al., 2011). Furthermore, epidemiologic
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studies show an increased incidence of Alzheimer’s disease in obese
individuals (Luchsinger and Gustafson, 2009, Naderali et al., 2009,
Mazon et al., 2017, Alford et al., 2018). Considering the rising numbers
of elderly individuals in the population due to demographic effects, the
potential impact of obesity on microglial morphology and cognitive
decline in elderly patients is of considerable interest.
In rodents, obesity-induced microglial activation especially in the
hypothalamus has been established (Morari et al., 2014. Baufeld et al.,
2016, Valdearcos et al., 2017). However, the underlying processes of
chronic obesity in humans are rather complex, and only few studies
outline the consequences of chronic obesity in the human brain. Baufeld
and colleagues detected an increased appearance of microglial cytor-
rhexis in hypothalami and frontal cortices of obese humans
(nobese= 12, nnon-obese= 9) and compared the microglial reaction in
obesity to what is seen in chronic diseases (Baufeld et al., 2016).
While diminishing cognitive function has been reported in over-
weight individuals (Siervo et al., 2011, Bischof and Park, 2015), several
studies have demonstrated increased internalization of synapses by
microglia after consumption of a high fat diet (Bocarsly et al., 2015,
Hao et al., 2016). Therefore, a potential impact of microglial dysfunc-
tion on reduced cognitive function should be considered in the context
of obesity. Obesity is also associated with significantly smaller hippo-
campal size (Raji et al., 2010).
Since the first description of a calcium binding protein specifically
localized in microglia (Ito et al., 1998), IBA1 has become the most
commonly employed marker for microglia. This protein, which shares
the proteomic sequence with allograft inflammatory factor 1 (AIF1), is
expressed by all microglial subpopulations (Ito et al., 1998, Sasaki
et al., 2001), as well as by peripheral macrophages (Sasaki et al., 2001,
Leone et al., 2006, Köhler, 2007, Buckman et al., 2014) and can be used
in thick sections suitable for neuropathological evaluation (Streit et al.,
2009).
In the current study, we examined microglia within the entorhino-
hippocampal area which is the first cortical region affected by
Alzheimer’s disease and important for short term memory (Braak and
Braak, 1991). We identified areas that were characterized by a loss of
IBA1-immunoreactivity in microglia but remained immuno-positive for
Gluthationperoxidase 1 (GPX1) and P2ry12. GPX1 in the brain is de-
scribed to be expressed primarily by microglial cells (Power and
Blumbergs, 2009), while P2yr12 is specific to intraparenchymal mi-
croglia (Mildner et al., 2017).
While initial qualitative assessments suggested that IBA1-negative
areas were more frequent in obese human beings, subsequent compu-
tational analysis did not confirm these results. Since some cases of non-
obese individuals also exhibited remarkable loss of IBA1, we searched
for possible confounders. Indeed, quantitative morphometry revealed
hepatic dysfunction to cause loss of IBA1-positive microglia suggesting
that impaired liver function can affect microglial phenotype and
biology in the brain.
2. Results
Analysing IBA1-stained sections, we observed great variability in
distribution of IBA1-positive microglia (Fig. 1). Areas with very dense
and evenly spread microglia were in close vicinity to areas with sparse
distribution. The areas lacking IBA1-labelling were not characterized by
structural tissue damage, such as microinfarcts (Fig. 2). Serial paraffin
sections (20 µm) were analysed to differentiate between a reduction in
microglial number or a downregulation of IBA1-expression. IBA1-ne-
gative areas showed remaining immunoreactivity for P2ry12 and GPX1,
demonstrating continued presence of microglia (Fig. 3). Some of these
areas also exhibited MHC-II and CD68-positive microglia. However,
staining for these antigens is difficult to interpret as immunoreactivity
is often lost in long term formalin-stored brain tissue likely because of
extensive crosslinking of antigens. Nevertheless, we propose that loca-
lized downregulation of IBA1 antigen occurs, rather than a loss of
microglia, thus reflecting an altered microglial immunophenotype.
Contrary to our expectations, we found GPX1 to be expressed con-
stitutively, even in young controls without sepsis. GPX1, a marker for
oxidative stress reactions (Lubos et al., 2011, Brigelius-Flohé and
Maiorino, 2013), was found to be expressed consistently in microglia
rather than in oligodendrocytes, astrocytes or neurons (Power and
Blumbergs, 2009). In comparison to IBA1, GPX1 staining appeared to
be more intense in the perinuclear somata of cells rather than in distal
processes (Fig. 3).
In order to inspect a seemingly higher frequency of IBA1-negative
areas in obese individuals, we compared 63 cases (nobese= 33, nnon-
obese= 30) and classified them by the appearance of areas with reduced
density and total loss of IBA1-labelling as described in Materials and
Methods (Fig. 4). Staging was conducted by three independent ex-
aminers, who found an increased frequency of IBA1-negative areas
(=Stage 2 cases) in obese individuals; however, testing the hypothesis
that the distribution of IBA1-negative areas of obese and non-obese are
equivalent, using a one-sided Wilcoxon rank sum test, could not be
rejected (p= 0.232, Fig. 5). Since some non-obese control cases ex-
hibited extreme loss of IBA1 staining, we searched for possible con-
founding variables in the medical histories of subjects. We found that
severe liver dysfunction, either being caused by alcohol abuse or in
some cases by malignant tumours, in our sample, tended to exhibit
decreased microglial density and loss in IBA1 staining even in non-
obese subjects. Therefore, we excluded these cases to reduce the (pos-
sible) confounding effects. Without liver dysfunction cases, testing the
hypothesis that the frequency of IBA1-negative areas is equivalent, the
one-sided Wilcoxon rank sum test statistic reached a p-value slightly
above the 5% significance level (nobese= 20, nnon-obese= 22,
p=0.052, Fig. 5) indicating that the hypothesis could not be rejected
at our chosen confidence level.
Since microglial density and an increased expression of IBA1 have
been described as “obesity and activation markers” (Thaler et al., 2012,
Baufeld et al., 2016), a more extensive computational analysis of mi-
croglial distribution was performed (Fig. 6). While there was a tendency
of higher microglial density in obese individuals in our sample, we were
not able to reject the hypothesis that microglial density in obese and
non-obese human hippocampi is equivalent (n=44, p= 0.620). Ex-
cluding cases with hepatic dysfunction did not change these results
(n= 26, p=0.285, Fig. 7). Further spatial analysis also did not show
any significant differentiation between obese and non-obese in-
dividuals. Therefore, we focused our investigations on the question, if
liver dysfunction in itself might be a driver for the processes that lead to
a reduction of IBA1-labelling and potential changes in microglial dis-
tribution.
We detected an increased mean empty space distance in patients
with liver dysfunction (nliver-dysfunction= 18, Øage= 64,82;
ncontrol = 26, Øage= 64,97) and were able to reject our hypothesis that
the mean empty space distance of patients with liver dysfunctions is the
same as for the patients that did not exhibit the dysfunction (p=0.016,
Fig. 8). Subsequent testing of the mean empty space distances in in-
dividuals with existing alcohol abuse exhibited similar results (nalcohol
abuse= 13, Øage= 64,28; ncontrol = 31, Øage= 64,99; p=0.013). Ex-
treme outliers in the control group did not have documented ethanol
abuse but showed liver dysfunction of other kinds (malignancies). Thus,
we concluded that the cause of liver function is not as important as the
actual effect of the dysfunction on the brain.
Hepatic encephalopathy as an end stage condition in liver disease is
connected to reduced consciousness and impaired cognitive function
(Felipo et al., 2012, Vilstrup et al., 2014, Arias et al., 2015). The typical
neuropathologic correlate is Alzheimer Type II-Astrocytosis, where af-
fected astrocytes are characterized by enlarged nuclei, deformation and
a thin cytoplasmic rim. The number of Alzheimer Type II-Astrocytes
was shown to correlate with intensity of hepatic encephalopathy and
while usually found in cortex, thalamus and striatum, it is absent in the
hippocampus (Butterworth et al., 1987, Norenberg 1987, Ciećko-
J. Lier et al. Brain Research 1710 (2019) 220–229
221
16
Fig. 1. Different regions from a single 100 μm section show striking differences in IBA-1 distribution. Scale bars: B: 500 μm; C, D: 100 μm.
Fig. 2. In comparison to IBA1-negative areas (Fig. 3), microinfarcts are surrounded by increased numbers of microglia with activated appearance (arrows) indicative
of structural tissue damage. Serial Sections A: IBA1. B: Nissl. C: H&E.
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Michalska et al., 2012). Our results demonstrate a significantly in-
creased mean empty space distances in liver dysfunction cases with AT
II-Astrocytosis (p= 0.028). Reducing the potential impact of obesity,
we excluded all obese cases and classified lean individuals by their liver
dysfunction. Since this led to a substantial reduction in sample size
(n=15), results demonstrate clear tendency (Fig. 8), however did not
stay significant after adjustment for multiple comparisons (p= 0.205).
To achieve comparability between our qualitative analysis and the
subsequent quantitative morphometry, we computed IBA1-negative
areas by analysing the thresholded distance value maps, preserving all
empty space distances exceeding 240 µm and multiplying the remaining
pixel count with the pixel area. Increased area size and frequency was
found in individuals suffering from alcohol abuse (p= 0.090), however
differentiation between obese and non-obese individuals was not pos-
sible.
Since a gradual alteration of hepatic structure and function is as-
sociated with aging (Le Couteur et al., 2008, Smiljanic et al., 2013), we
examined potential age-related effects on our findings. No correlation
with aging was found neither in all individuals (n=44, p=0.112,
r= -0.243), nor in the individuals without hepatic impairment (n= 26,
p=0.482, r= 0.144) or in only lean individuals (n= 15, p=0.676,
r= -0.118), and we conclude that loss of IBA1 immunophenotype does
not occur as a consequence of (accelerated) microglial senescence
(Supplemental Fig. 1).
3. Discussion
The current study has shown effects of liver dysfunction, a systemic
disorder, on microglial distribution and expression of IBA-1, but was
not able to detect clear differences between normal weight and obese
individuals in the human hippocampus.
Obesity has been described to increase microglial activation and
IBA1-expression in the hypothalamus (Thaler et al., 2012, Baufeld
et al., 2016, Valdearcos et al., 2017), and it was shown that this effect is
induced by high fat diet rather than by increased fat mass per se, since
ob/ob mice did show microglial activation comparable to wild type
Fig. 3. Direct comparison of different microglial markers and other cell-specific markers shows positive P2ry12 and GPX1 staining in IBA1-negative areas. This
suggests a local downregulation of IBA1-antigen.
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controls that were fed standardized chow diet (Gao et al., 2014). Most
studies examining microglia in obesity have been focused on the hy-
pothalamus and have demonstrated microglial activation solely in the
hypothalamus after short term application (2–3weeks) of high fat diet
(Thaler et al., 2012). In contrast, microglial activation in the hippo-
campus was exhibited after long-term application (> 20weeks) as well
as cognitive deficits (Lu et al., 2011, Jeon et al., 2012, de Luca et al.,
2016). As a morphological correlate, studies mimicking the effects of
long term (eight month) western diet in mice (Graham et al., 2016)
detected increased appearance of IBA1-positive cells in rodent hippo-
campi.
Searching for obesity-induced effects on microglial appearance in
human individuals, we detected a tendency towards increased density
of IBA1 staining in hippocampi in our sample, but results did not reach
statistical significance. So, in contrast to reproducible alterations in
hypothalamic experiments, the size of the obesity-induced effect in the
human hippocampus either is too small to be detected within the pre-
sent small sample size or there is none at all. Additionally, we were not
able to characterize obese cases by distributional differences in micro-
glial appearance. However, we identified significantly increased mean
empty space distances and increased size of areas lacking IBA1-ex-
pression in individuals suffering from liver dysfunction and docu-
mented alcohol abuse, suggesting an effect of hepatic impairment on
microglial phenotype. These findings extend previous observations re-
porting enhanced astrocytosis in individuals with liver dysfunction
(Butterworth et al., 1987, Norenberg 1987, Ciećko-Michalska et al.,
2012). While astrocytic changes in hepatic encephalopathy were known
since the early 20th century (Scherer 1933, Adams and Foley 1953),
recent studies described microglial proliferation and dystrophy in late
stages in human samples (Dennis et al., 2014).
After being classified as either resting (ramified) or activated
(hypertrophic) phenotypes for most of their history, a third, dystrophic
microglial phenotype, thought to reflect microglial senescence, was
described (Streit et al., 2004). Dysfunction of lysosomal pathways was
proposed to contribute to the formation of this senescent microglial
phenotype (Safaiyan et al., 2016), which has been associated with
aging-dependent functional impairment (Spittau 2017). The appear-
ance of dystrophic microglia precedes tau pathology in Alzheimer dis-
ease brains (Streit et al., 2009), and such immune aging has been linked
causally to the pathogenesis of the disease (Streit et al., 2014, Galatro
et al., 2017, Soreq et al., 2017). In general, microglial aging is evolving
as a novel field and this process could not be fully mimicked in mice
(Franco Bocanegra et al., 2018, Navarro et al., 2018), but western diet
and chronic phagocytosis of myelin causes a dystrophy-like phenotype
(Graham et al., 2016, Safaiyan et al., 2016).
Since we were not able to detect a relationship between IBA1-ne-
gative areas and aging, loss of IBA1 is not likely to be part of microglial
senescence. Additionally, alcohol intake has been repeatedly reported
to decrease the risk for Alzheimer’s disease (Peters et al., 2008, Anstey
et al., 2009, Hersi et al., 2017), which is closely associated with mi-
croglial senescence. To explain the changes in individuals with im-
paired liver function, we propose the existence of a second dysfunc-
tional microglial state, which is characterized by the loss of IBA1. Even
though the IBA1 antigen is commonly used as a microglial marker, its
exact function still needs to be elucidated. Public data analysis
(Stringdb, www.string-db.org) demonstrated the paucity of available
information on IBA1 function and its interaction networks. IBA1 is one
of four different proteins, which share the same genomic sequence and
apparently do not undergo post- transcriptomic changes (Deininger
et al., 2002). A more expansive analysis including protein functions and
networks is needed to be able to fully understand our results and the
changes of microglial function in chronic diseases. The spatial analysis
Fig. 4. Staging. A: Stage 0. Equally distributed microglia, no obvious changes in microglial density visible. B: Stage 1. Areas of reduced density, but no areas with
complete loss of IBA-1-labelling. C: Stage 2. At least one area with complete loss of IBA-1-labelling. Diameter of at least 480 μm was used to describe IBA-1-negative
areas. Blood vessels were not included in measurement of radii. D: Stage 3. Almost no IBA-1-labelling. The cells one can see are neurons, stained by the hematoxylin
counterstaining. Also visible in E as it is a magnified area of D. Scale bars: A, C, D 100 μm; B 250 μm, E 25 μm.
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shown here stresses the importance of not only considering the mor-
phological appearance of individual microglia, but also their im-
munophenotype and distribution throughout the brain in chronic sys-
temic disease.
Since we do see normally distributed and evenly spread microglia in
some cases with liver dysfunction and with obesity, additional un-
known variables could play a role. Similar observations were made
studying cognitive deficits in obese individuals (Kuo et al., 2006, West
and Haan, 2009), implying protective effects in some individuals.
Considering that the risk for developing liver impairment increases with
higher body mass index (Ruhl and Everhart 2003, Fabbrini et al., 2010)
and that additional metabolic, cardiovascular and endocrine abnorm-
alities are commonly found in obese, further analysis needs to be done
to comprehend the single effects of obesity and liver dysfunction on
microglial morphology and function, but also the combined effects as
they are most authentic in humans.
4. Material & Methods
4.1. Immunohistochemistry
After approval through the consent form of the University Hospital
Leipzig, tissue was provided by the Department of Neuropathology in
Leipzig. Tissue was fixed in 4% aqueous solution of formaldehyde be-
fore embedding in paraffin or polyethylenglycol (PEG). 96 human brain
samples were taken from the hippocampal region (Table 1,
Supplemental Fig. 2). Obese cases were defined having a body mass
index (BMI) score of 30 or more, whereas lean individuals had a score
of 25 or less. All experiments were conducted in accordance with the
Helsinki Declaration of 1975.
For paraffin serial sections (20 µm) we performed Nissl and H&E
staining, as well as immunohistochemistry for a variety of microglia/
macrophage markers and GFAP (Table 2). To achieve the best possible
IBA1 staining, different antibodies (WAKO, Synaptic Systems) were
applied and compared. By using microwave pretreatment in citrate
buffer (95 °C, 5min.) antigen retrieval was achieved. Then sections
were treated with 1.5% H2O2 in Methanol for 20min. To prevent
nonspecific binding, tissue was blocked with 1% bovine serum albumin
(BSA, Sigma-Aldrich, A7906) in PBS/Triton (0.03%, PBS-T). Subse-
quently, primary antibodies were incubated overnight in 4 °C in the
adequate dilution in 0.5% BSA in PBS-T. After rinsing with PBS-T, the
biotinylated secondary antibodies were applied and incubated for
90min at room temperature (1:100, Table 2), followed by peroxidase
treatment (extrAvidin-Peroxidase, Sigma-Aldrich E2886). Peroxidase
activity was developed using 3,3′ Diaminobenzidine tetrahydrochloride
(DAB, Sigma-Aldrich D5905) as a chromogen. After counterstaining
using hematoxylin, sections were washed, dehydrated and mounted.
The P2ry12 staining was performed according to a protocol established
by Mildner and colleagues (Mildner et al., 2017).
PEG-Sections (100 µm) were stained in free floating manner. No
microwave pretreatment was performed.
4.2. Staging
PEG-sections were used for staging (Table 1). Stage 0 represents
dense and evenly spread microglial appearance, whereas Stage 1 is
characterized by partially reduced density in IBA1-expression. Identi-
fication of Stage 2 was based on one or more areas lacking IBA1-ex-
pression, with a diameter of at least 480 µm. The size was chosen ar-
bitrarily considering the threshold value in the computational-based
analysis. Stage 3 was defined as almost no IBA1 staining (Fig. 4). Three
independent and blinded examiners performed the staging. The groups
were similar regarding age and post mortem interval. To minimize
possible interactions, we excluded individuals with hepatic diseases like
Fig. 5. A: Staging results in all individuals (n= 63) sorted according to weight. B: Frequency plot of stages in all individuals (p= 0.232) shows a tendency, but no
significant difference. C: Staging results in the individuals without any hepatic constraints (n= 42). D: Frequency plot of staging in individuals without any
impairment in liver function (p=0.052). Plots show a higher frequency of IBA1-negative areas in obese individuals.
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cirrhosis or hepatic carcinoma. If the three examiners disagreed in ca-
tegorizing one individual, the median stage of the three examiners was
assigned to the respective patient. Statistical analysis was performed
using this median value. Due to the available research conducted on
this topic, we hypothesized that microglial cells in obese individuals are
more heavily impaired than in normal weight controls and conducted a
one-sided Wilcoxon rank sum test on the median category of the three
examiners to test our hypothesis. P-values were calculated assuming a
normal approximation of the resulting test statistic without continuity
correction (using R core’s wilcoxon.test function, R version 3.4.4, http://
www.R-project.org). Computing exact p-values and application of
continuity correction did not change results fundamentally (p-
value±0.03).
4.3. Computational analysis
To investigate differences in the overall distribution of microglia in
IBA1-stained sections a computational analysis was performed.
Therefore, paraffin sections (20 µm, Table 1) were fully digitalized
using a digital slide scanner (Pannoramic Scan II, 3D HISTECH Ltd.,
Budapest, Hungary). Images of stained tissue slices were exported from
slide scanner data sets (Pannoramic Viewer, version 1.15.4., 3D HIS-
TECH Ltd., Budapest, Hungary) in PNG format with pixel dimension of
0.972 µm. Separating colour channels was accomplished using the
“Colour Deconvolution” plugin for ImageJ (1.51r, http://imagej.hih.
giv/ij). After transformation of the original images into separate grey-
scale images, blue channels were subtracted to avoid misdetections
based on the hematoxylin staining (Mathematica, Version 11.1,
Fig. 6. A: Detection process. Original scan was converted into greyscale image. Application of binarization using local threshold resulted in transformation of the cells
into white signals. The Centres of microglial signals were then determined and saved as data points. The detection process was followed by the skeletonization B:
Schematic visualisation of skeletonization (data points are represented as black squares). Distance transformation leads to assignation of distance value to each pixel
located between the data points. Maximum distance values between data points were determined by skeletonization of blank areas (white squares). All measurements
were performed along the skeleton (grey squares). By using the skeletonization we prioritized centres of blank areas and excluded the bias of lower distance values
adjacent to the data points C: Original scan of 20 μm thick paraffin section. D: The image mask defines the borders within data points are detected. E: Heatmap of
Mean Empty Space Distance. Brighter colours indicate longer distances between the single signals. F: Inserted histogram visualizes the distribution of mean empty
space distances in the heatmap shown in E. The x-axis marks the distance value, while the y-axis displays the frequency of the specific distances. It indicates that most
distances between data points are around 50 µm. G: Detection of IBA1-negative areas. All areas with Empty space distances exceeding 240 μm are included to
calculate the size of Iba1-negative areas.
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Wolfram Research, Inc, Champaign, IL, USA)). Subsequently, local
thresholding (Auto local Threshold plugin for ImageJ, Niblack-Filter
[radius= 210, parameter 1=4, parameter 2=0]) was performed. For
summarizing nearby microglial signals, morphological closing (“Mor-
phoLib” plugin for ImageJ [closing radius= 7.5]) was applied. Re-
duction of image noise was accomplished by removing small particles
(“Analyze particles” plugin for ImageJ [size < 15 pixels]). Centres of
remaining microglial signals were then determined and saved as data
points.
Image masks covering the image sections were generated. However,
some regions needed to be masked by hand (Adobe Photoshop CS6,
Adobe Systems Inc., San Jose, USA) to remove artefacts such as tissue
overlaps, dirt, ruptured areas and DAB-accumulations in peripheral
image areas. Original images were superimposed on the respective
image masks, and only data points within the image mask were em-
ployed in the analysis. For each image the number of data points and
density (number of points divided by mask area) were determined.
Application of a distance transformation calculated a map of empty
space distances (ESD) of all image pixels located in between the data
points. Maximum distance values between data points were determined
by skeletonization of blank areas. In principle, the area around the data
points was increased circularly until outer lines collided with areas of
contiguous data points. Resulting collision lines represent the median
lines, or skeleton, of the blank areas. The skeleton was then super-
imposed onto the distance map of the respective image and distance
values covered by the skeleton were extracted. Values were averaged to
compute mean empty space distance (MESD) as well as the standard
deviation (SD). By using the skeletonization we prioritized the centers
of blank areas and excluded the bias of lower distance values adjacent
to the data points (Leal-Egaña et al., 2011). Calculation of IBA1-nega-
tive areas was performed by thresholding the distance value maps,
preserving all empty space distances exceeding 240 µm. This value was
Fig. 7. IBA-1-Density as a parameter is often used to describe differences between lean and obese individuals. Results show tendency, but do not reach significance.
A: All individuals (p= 0.620). B. All individuals without those with hepatic impairment (p= 0.285). This parameter mirrors best the results we obtained through the
staging.
Fig. 8. Mean Empty Space Distance and Iba1-negative area showing significant differences between individuals with impaired liver function and healthy controls
(n=44). A: Mean empty space distance of all individuals separated by liver function (p= 0.016). B: Abuse of ethanol often precedes or accompanies liver dys-
function (p=0.013). Extremes in the control group do not have documented abuse of ethanol but do present severe liver dysfunction with Alzheimer Type II-
Astrocytosis. C: Presence of Alzheimer Type II-Astrocytosis is a key indicator of hepatic encephalopathy, occurring in end stage liver disease (p= 0.028). D:
Considering our previous results and the influences of obesity on liver function, we examined the Mean Empty Space Distance in normal weight individuals, classified
according to the presence of liver impairment. Results demonstrate a clear tendency towards higher distances between IBA1-positive microglia in normal weight
individuals with impaired liver function. Due to the reduced sample size (n= 15) results did not remain significant after p-value adjustment for multiple com-
parisons. E-H: Size of area of IBA1-negativity was calculated considering the amount of distances between data points over 240 μm. E: Shows distribution of all
individuals (p= 0.216). Moreover, the results demonstrate, that all extreme outliers in this category suffer from liver dysfunction. F: (p=0.090). G: Results show no
significant difference, but a tendency similar to the previous results. Outliers in control group suffer from liver disease and C2 abuse, without documented Alzheimer
Type II-Astrocytosis (p= 0.884). H: Possibly due to the lower sample size in this category, significance is not reached; however, a trend is apparent.
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set arbitrarily, after visual analysis of the case-related heatmaps to
define a threshold value. Areas were computed by multiplying the re-
maining pixel count with the pixel area (0.945 µm2).
Statistical analysis was performed with IBM SPSS Statistics (version
22, IBM Corp., Armonk, New York, USA). Calculated parameters were
separated into analysis groups. These groups were tested for normal
distribution using Shapiro-Wilk Test. For normally distributed data,
parametric tests (t-test), otherwise nonparametric tests (Mann-Whitney
U test) were applied. To adjust the p-value for multiple comparisons,
post-hoc Bonferroni correction was performed. The significance level
was set at [alpha]= 0.05.
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Microglia, the brain’s resident phagocytes, derive from yolk sac macrophages,
which reach the brain early in development. Complying important functions for
homoeostasis, synaptic transmission, plasticity, and immune defence, microglia have
been shown to be self-renewing and long-lived. In rodent animals, two microglial
phenotypes types were differentiated: resting microglia, which survey the surrounding
with their long processes, and activated microglia, which migrate to lesion sites to
phagocyte destroyed tissue or prevent invasion of infectious agents. Not even two
decades ago, a third form was described, which was characterized by dystrophy and
cytorrhexis and was being found in brains of elderly human patients.
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Furthermore, microglial changes frequently have been described in context with
obesity. Especially studies in the hypothalamus repeatedly described microglial
activation due to high-fat diet and obesity. In humans, increased cytorrhexis was
found. Since the importance of microglial function for synaptic plasticity and the
frequently described decrease of cognitive functions in obesity, the hippocampus as
a center for memory functions in the brain was of special interest for us.
In 100µm thick, IBA1-stained sections of human hippocampi, we detected areas
that were seemingly devoid of microglia. These areas were not clearly confined, thus
not representing microinfarctions.
An expansive panel of microglial markers was employed to examine the possible
loss of microglial cells. MHCII and CD68 were the best-known markers, however they
proved to be difficult to analyze due to the variable extent of staining in the longtime
stored tissue, likely because of extensive cross-linking of antigens. Especially, P2ry12,
a highly specific microglial marker, and Gluthathionperoxidase 1 (GPX1) showed
sufficient stability to label microglia.The analysis of serial sections exhibited adequate
stainings of these markers in IBA1-negative areas. Therefore, we propose a local
downregulation of IBA1 expression rather than a local loss of microglia. Furthermore,
GFAP and routine stainings like HE and Nissl were analyzed to exclude overall tissue
damage.
A first impression led to the hypothesis that IBA1-negative areas occur more often
in obese individuals. Therefore, a staging was established, comprising four categories:
thoroughly and evenly spread microglial distribution, local reduction of IBA1-positive
microglial density, areas fully devoid of IBA1 and almost no IBA1-staining in the whole
section at all.
Examining 63 cases (nobese =33, nnon-obese = 30), no significant difference in
the occurrence of IBA1-negative areas in obese individuals (p=0.232) was found.
Therefore, the hypothesis that IBA1-negative areas appear more often in brains of
obese patients was rejected. To investigate possible confounders, we examined
non-obese cases tending to exhibit decreased microglial density and pronounced
loss of IBA1-expression. A majority of these cases suffered from liver dysfunction,
either being caused by alcohol abuse or (rarely) by malignant tumors. Therefore,
we excluded liver dysfunction to reduce possible confounding effects. However, we
were not able to reject the hypothesis that IBA1-negative areas appear more often in
obese cases shortly above the 5% confidence level (p=0.052).
Since this method might not be able to discriminate slight changes well enough, a
computational analysis to investigate further distributional changes of IBA1-positive
26
microglia in obese and individuals suffering from liver dysfunction was conducted.
Paraffin Sections of 44 individuals were fully digitalized using a digital slide
scanner. Subsequently, images were processed to attain black and white (= binary)
images. Every cell signal was saved as a data point. Since it is often used as an
activation marker, we primarily calculated the overall density of microglial signals.
However, no significant differences were found to differentiate obese and lean indi-
viduals (p=0.620). Excluding cases with hepatic dysfunction did not change these
results (n=26, p=0.285). To detect underlying changes in the microglial distribution
we employed a method called skeletonization. Essentially, the areas in between the
data points were assigned to distance values: the further away from a data point
the higher the value. Therefore, the distance values increase when moving away
from a data point and decrease again when approaching the adjacent data point.
The borderline values, representing the highest distance in between two adjacent
data points, were used to form a skeleton covering the whole image. The skeleton
was then employed to calculate the spatial analysis. An advantage of this method is
that small values adjacent to the data points, which might bias the result, are less
weighted. Therefore, a focus on empty areas is set.
The mean empty space distances were not increased in obese individuals
(p=0.428) but were increased in patients with liver dysfunction (nliver dysfunction=18,
Øage=64,82; ncontrol=26, Øage=64,97, p=0.016). Further analyses demonstrated
that the cause of liver dysfunction (e.g. alcohol abuse, malignant tumour) did not
influence the results. Since the end-stage condition of liver dysfunction – hepatic
encephalopathy – is characterized by cognitive decline, we examined the occurrence
of distributional changes in microglia in brains with an astrocytic reaction, a sign of
hepatic encephalopathy. Here, too, an increased mean empty space distance was de-
tected (p=0.028). Classification of only lean individuals led to a substantial reduction
in sample size (n=15). The results demonstrated a clear tendency towards increased
distances between the cells, however it did not stay significant after adjustment for
multiple comparisons (p=0.205).
The differences shown visualize changes in microglial distribution in individuals suf-
fering from a chronic disease like liver dysfunction. The computational analysis
is dependent on different factors. The color-based cell detection mechanism and
varying quality of staining make the analysis difficult. By manually inspecting and
reworking the detected signals, we tried to diminish these weaknesses.
Widespread microglial fragmentation, a distinctive feature of microglial senes-
cence, was described in hepatic encephalopathy. Therefore, we were interested
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if the increase in mean empty space distance and IBA1-negative areas was age-
dependent to evaluate a possible relation of liver-induced changes and accelerated
microglial aging. The distributional alterations were correlated to age. However, no
age dependency was found neither in all individuals (n=44, p=0.112, r=-0.243), nor in
the individuals without hepatic impairment (n=26, p=0.482, r=0.144) or in only lean
individuals (n=15, p=0.676, r=-0.118) suggesting that changes do not occur because
of accelerated microglial senescence, but due to a distinct morphological phenotype
related to the chronic systemic disease caused by liver dysfunction.
Microglia are currently differentiated in the three phenotypes ramified, activated
and senescent. If these three states can sufficiently describe the full portfolio of
microglial morphology and function, needs to be thoroughly discussed. The slow but
constant microglial renewal has been shown to adapt individual cells and their spatial
layout to altering environments, making a more dynamic view on microglial function
and morphology inevitable.
Further studies are needed to evaluate the distinct consequences of obesity and liver
dysfunction on microglial function and morphology. Furthermore, individuals, who,
despite having several comorbidities, present a physiological microglial distribution
need to be examined to identify potential protective factors.
28
5 Bibliography
Adams R. D., Foley J. M. The neurological disorder associated with liver disease // Research
publications - Association for Research in Nervous and Mental Disease. 1953. 32. 198–237.
Albrecht Jan, Norenberg Michael D. Glutamine: A Trojan horse in ammonia neurotoxicity // Hepatology
(Baltimore, Md.). 2006. 44, 4. 788–794.
Arias N., Méndez M., Arias J. L. Differential contribution of the hippocampus in two different demanding
tasks at early stages of hepatic encephalopathy // Neuroscience. 2015. 284. 1–10.
Askew Katharine, Li Kaizhen, Olmos-Alonso Adrian, Garcia-Moreno Fernando, Liang Yajie, Richardson
Philippa, Tipton Tom, Chapman Mark A., Riecken Kristoffer, Beccari Sol, Sierra Amanda, Molnár
Zoltán, Cragg Mark S., Garaschuk Olga, Perry V. Hugh, Gomez-Nicola Diego. Coupled Proliferation
and Apoptosis Maintain the Rapid Turnover of Microglia in the Adult Brain // Cell reports. 2017. 18,
2. 391–405.
Atagi Yuka, Liu Chia-Chen, Painter Meghan M., Chen Xiao-Fen, Verbeeck Christophe, Zheng Honghua,
Li Xia, Rademakers Rosa, Kang Silvia S., Xu Huaxi, Younkin Steven, Das Pritam, Fryer John D.,
Bu Guojun. Apolipoprotein E Is a Ligand for Triggering Receptor Expressed on Myeloid Cells 2
(TREM2) // The Journal of biological chemistry. 2015. 290, 43. 26043–26050.
Baufeld Caroline, Osterloh Anja, Prokop Stefan, Miller Kelly R., Heppner Frank L. High-fat diet-induced
brain region-specific phenotypic spectrum of CNS resident microglia // Acta neuropathologica.
2016. 132, 3. 361–375.
Bischof Gérard N., Park Denise C. Obesity and Aging: Consequences for Cognition, Brain Structure,
and Brain Function // Psychosomatic medicine. 2015. 77, 6. 697–709.
Bocarsly Miriam E., Fasolino Maria, Kane Gary A., LaMarca Elizabeth A., Kirschen Gregory W.,
Karatsoreos Ilia N., McEwen Bruce S., Gould Elizabeth. Obesity diminishes synaptic markers,
alters microglial morphology, and impairs cognitive function // Proceedings of the National Academy
of Sciences of the United States of America. 2015. 112, 51. 15731–15736.
Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes // Acta Neuropathologica.
1991. 82, 4. 239–259.
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Köhler Christoph. Allograft inflammatory factor-1/Ionized calcium-binding adapter molecule 1 is
specifically expressed by most subpopulations of macrophages and spermatids in testis // Cell and
tissue research. 2007. 330, 2. 291–302.
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Manuel, Kettenmann Helmut. The Big-Bang for modern glial biology: Translation and comments on
Pı́o del Rı́o-Hortega 1919 series of papers on microglia // Glia. 2016. 64, 11. 1801–1840.
Sierra Amanda, Encinas Juan M., Deudero Juan J. P., Chancey Jessica H., Enikolopov Grigori,
Overstreet-Wadiche Linda S., Tsirka Stella E., Maletic-Savatic Mirjana. Microglia shape adult
hippocampal neurogenesis through apoptosis-coupled phagocytosis // Cell stem cell. 2010. 7, 4.
483–495.
Siervo M., Arnold R., Wells J. C. K., Tagliabue A., Colantuoni A., Albanese E., Brayne C., Stephan
B. C. M. Intentional weight loss in overweight and obese individuals and cognitive function: A
systematic review and meta-analysis // Obesity reviews : an official journal of the International
Association for the Study of Obesity. 2011. 12, 11. 968–983.
Soreq Lilach, Rose Jamie, Soreq Eyal, Hardy John, Trabzuni Daniah, Cookson Mark R., Smith Colin,
Ryten Mina, Patani Rickie, Ule Jernej. Major Shifts in Glial Regional Identity Are a Transcriptional
Hallmark of Human Brain Aging // Cell reports. 2017. 18, 2. 557–570.
Spencer Sarah J., Basri Bashirah, Sominsky Luba, Soch Alita, Ayala Monica T., Reineck Philipp,
Gibson Brant C., Barrientos Ruth M. High-fat diet worsens the impact of aging on microglial function
and morphology in a region-specific manner // Neurobiology of Aging. 2019. 74. 121–134.
Spencer Sarah J., D’Angelo Heather, Soch Alita, Watkins Linda R., Maier Steven F., Barrientos
Ruth M. High-fat diet and aging interact to produce neuroinflammation and impair hippocampal-
and amygdalar-dependent memory // Neurobiology of Aging. 2017. 58. 88–101.
Spittau Björn. Aging Microglia-Phenotypes, Functions and Implications for Age-Related Neurodegen-
erative Diseases // Frontiers in aging neuroscience. 2017. 9. 194.
Streit Wolfgang J., Braak Heiko, Del Tredici Kelly, Leyh Judith, Lier Julia, Khoshbouei Habibeh,
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Supplementary Figure 1: Correlation of mean empty space distance and age shows no re-
lationship. A: All Individuals (n=44, p=0.112, r=-0.243). B: Individuals without hepatic
impairment (n= 26, p=0.482, r=0.144). C = Only lean individuals (n = 15, p=0.676, r=-0.118).
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study-ID Paraffin PEG sex age BMI cause of death PMI
2 PEG m 50 25 pneumonia 1
9 Paraffin f 81 33 heart failure 2
13 Paraffin PEG f 62 42 liver failure 1
14 Paraffin PEG f 81 40 heart attack 1
44 PEG f 65 25 malignom 1
53 Paraffin PEG f 65 44 maliognoma 2
54 PEG m 59 39 heart attack 2
58 Paraffin PEG f 71 23 amyloidosis 1
62 Paraffin f 58 52 septic shock 3
64 Paraffin PEG m 52 20 hemorrhagic shock 2
65 PEG m 48 18 respiratory insufficiency 2
69 PEG m 54 23 Infection 0
72 PEG f 62 25 heart failure 1
79 Paraffin PEG m 81 24 heart failure 1
83 Paraffin PEG m 45 23 liver failure 2
85 PEG f 75 24 lung embolism 2
87 PEG f 78 39 Infection 1
94 PEG f 80 23 chronic ischaemic heart disease 2
95 Paraffin PEG f 66 49 septic shock 2
100 Paraffin f 62 39 liver failure 1
134 Paraffin f 88 21 lung embolism 3
154 Paraffin m 72 42 liver failure 1
160 PEG m 75 22 chronic ischaemic heart disease 1
235 PEG m 57 24 liver failure 2
266 PEG m 61 35 malignoma 2
267 Paraffin PEG m 69 35 lung embolism 1
270 PEG f 60 49 septic shock 2
272 PEG m 61 41 hemorrhagic shock 2
280 PEG m 58 46 lung embolism 1
298 PEG f 72 24 lung embolism 1
308 PEG m 65 42 chronic ischaemic heart disease 1
322 PEG f 71 35 liver failure 1
333 PEG f 69 44 septic shock 2
347 PEG m 49 48 liver failure 2
350 PEG m 68 22 heart failure 1
355 PEG m 79 35 pneumonia 2
364 PEG m 62 24 ARDS 2
365 PEG m 64 24 liver failure 1
369 PEG f 70 32 heart failure 0
370 PEG f 80 38 hypertensive heart disease 2
374 PEG f 89 20 chronic ischaemic heart disease 2
377 PEG m 60 38 pneumonia 2
384 PEG m 76 30 pneumonia 2
401 PEG f 52 22 respiratory insufficiency 2
406 Paraffin m 65 32 hemorrhagic shock 3
416 Paraffin f 46 24 liver failure 3
423 Paraffin f 65 32 liver failure 3
429 PEG m 52 30 liver failure 0
39
430 PEG m 44 62 heart failure 2
437 PEG f 64 23 malignoma 1
443 PEG f 63 25 liver failure 1
444 PEG f 58 23 pneumonia 1
446 PEG m 62 35 cerebral hemorrhage 2
447 Paraffin PEG f 57 30 hemorrhagic shock 1
449 Paraffin f 59 44 liver failure 1
465 PEG m 78 23 pneumonia 2
467 PEG f 78 42 lung embolism 2
476 Paraffin m 86 24 chronic ischaemic heart disease 1
482 PEG m 64 21 heart failure 1
486 PEG m 90 25 pneumonia 2
513 PEG m 52 25 lung embolism 1
531 PEG m 64 43 liver failure 2
584 PEG f 79 23 infection 1
585 PEG f 78 33 heart failure 1
604 Paraffin m 54 36 liver failure 3
615 Paraffin f 73 24 chronic ischaemic heart disease 2
626 PEG m 85 24 respiratory insufficiency 1
627 PEG m 66 24 pneumonia 1
640 PEG m 42 23 ARDS 1
650 PEG m 65 32 liver failure 1
699 Paraffin m 62 21 ARDS 1
704 Paraffin f 59 23 heart attack 2
708 Paraffin m 56 39 heart attack 1
720 Paraffin m 68 20 malignoma 1
726 Paraffin m 53 22 lung embolism 3
728 Paraffin f 48 34 ARDS 3
739 Paraffin f 43 39 liver failure 3
741 Paraffin m 74 24 heart attack 2
752 Paraffin f 58 23 pneumonia 3
756 Paraffin m 76 32 pneumonia 2
790 PEG f 63 31 chronic ischaemic heart disease 1
798 PEG m 58 37 heart attack 2
807 PEG m 69 34 heart attack 2
820 Paraffin f 69 40 heart failure 2
826 PEG m 60 32 heart failure 1
902 Paraffin PEG m 50 33 ARDS 1
903 Paraffin m 65 44 Infection 3
972 Paraffin m 76 30 rejection reaction 3
1009 Paraffin f 73 31 heart failure 1
1057 Paraffin m 54 33 liver failure 2
1062 Paraffin m 59 37 liver failure 1
1075 Paraffin f 84 41 Infection 2
1076 Paraffin f 84 37 heart attack 1
1077 Paraffin m 62 33 pneumonia 1
1079 Paraffin m 68 31 ARDS 3
1102 Paraffin m 57 31 liver failure 1
Supplementary Figure 2: Overview of all cases used in the experiments.
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